To ask the Secretary of State for Health, what steps his Department is taking to ensure that patients with chronic myeloid leukaemia in England have access to (a) Ponatinib and (b) other innovative new medicines.
21 July 2015
A number of drugs for the treatment of chronic myeloid leukaemia have been recommended by the National Institute for Health and Care Excellence and are routinely available in England.
A number of other drugs, including ponatinib, are available through the Cancer Drugs Fund.
We take the issue of ensuring rapid access to innovative therapies very seriously, which is why we have launched an Accelerated Access Review to make recommendations to Government later in the year on speeding up access for National Health Service patients to innovative and cost effective new medicines, diagnostics and medical technologies.